1. Berger Montague investigates potential fraud claims against RxSight. 2. RxSight's LDD sales and revenue declined significantly in Q2 2025. 3. Shares plummeted 37% after disappointing performance revealed. 4. Investors can seek lead plaintiff status by September 22, 2025. 5. CXST faced adoption challenges leading to revised revenue guidance.
The significant share drop post-revenue guidance highlights investor distrust, impacting future confidence. Historical examples indicate similar situations often lead to prolonged price declines.
The ongoing investigation into potential fraud significantly undermines investor sentiment and confidence in RxSight.
The immediate effect is seen from the fraud investigation and recent revenue drop. If claims progress, further negative sentiment is likely short-term.
PHILADELPHIA, Aug. 26, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors in RxSight, Inc. ("RxSight" or the "Company") (NASDAQ:RXST).
RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery. Its RxSight system involves the Company's Light Delivery Device (LDD).
On July 8, 2025, RxSight revealed significant declines in LDD sales, LAL utilization, and overall revenue in Q2 2025, also lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz disclosed at that time that "[a]doption challenges over the last few quarters have been a primary reason for the LDD stall."
On this news, RxSight shares fell $4.84, or 37%, to a close of $7.95 per share on July 9, 2025.
If you acquired RxSight stock during the Class Period of November 7, 2024 through July 8, 2025, you may seek lead plaintiff status in the case by September 22, 2025. The lead plaintiff represents other harmed investors in the litigation.
If you are an RxSight investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger Montague
Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE. The Firm has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-berger-montague-advises-rxsight-inc-nasdaq-rxst-investors-to-inquire-about-a-securities-fraud-class-action-by-september-22-2025-302539061.html
SOURCE Berger Montague